BMO Capital analyst Joanne Wuensch started Tandem Diabetes with an Outperform rating and $77 price target. Manufacturers are consolidating as pump utilization is increasing and Tandem's product pipeline is differentiated, Wuensch tells investors in a research note. Further, the company's momentum "is evident" as its Q4 revenue increased 91% year-over-year and its and gross margins rose 1,060 basis points, adds the analyst. Over time, Wuensch expects more of the 3.3M U.S. insulin-dependent patients to migrate to pumps.
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here